NCT07018544View on ClinicalTrials.gov

A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea

Enrolling by invitationOBSERVATIONAL
Enrollment

840

Participants

Timeline

Start Date

November 19, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Obesity and Overweight
Interventions
OTHER

semaglutide

Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.

Trial Locations (8)

10475

MyongJi Hospital, Goyang-si

16499

Ajou University Hospital, Gyeonggi-do

31019

Yonsei Hanaro Clinic, Chungcheongnam-do

35220

Daejeon Endo Internal Medicine Clinic, Daejeon

49267

Kosin University Gospel Hospital, Busan

50612

Pusan National University Yangsan Hospital, Yangsan

06351

Samsung Medical Center, Seoul

08779

Hplus Yangji Hospital, Seoul

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY